1. Home
  2. GXAI vs LNAI Comparison

GXAI vs LNAI Comparison

Compare GXAI & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gaxos.ai Inc.

GXAI

Gaxos.ai Inc.

HOLD

Current Price

$1.18

Market Cap

12.3M

Sector

N/A

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

HOLD

Current Price

$3.26

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GXAI
LNAI
Founded
2021
N/A
Country
United States
United States
Employees
N/A
29
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
11.8M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
GXAI
LNAI
Price
$1.18
$3.26
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.3M
674.9K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
71.35
N/A
EPS
N/A
N/A
Revenue
$1,933,030.00
N/A
Revenue This Year
$271.23
N/A
Revenue Next Year
$36.32
N/A
P/E Ratio
N/A
N/A
Revenue Growth
47901.74
N/A
52 Week Low
$1.02
$0.15
52 Week High
$2.96
$5.02

Technical Indicators

Market Signals
Indicator
GXAI
LNAI
Relative Strength Index (RSI) 44.72 57.09
Support Level $1.06 $0.57
Resistance Level $1.32 $3.38
Average True Range (ATR) 0.07 0.59
MACD -0.01 -0.02
Stochastic Oscillator 29.06 33.54

Price Performance

Historical Comparison
GXAI
LNAI

About GXAI Gaxos.ai Inc.

Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: